Plasminogen activators are enzymes found in all vertebrate species investigated so far. Their physiological function is the generation of localized proteolysis in the context of tissue remodeling, wound healing and neuronal plasticity. The common vampire bat (Desmodus rotundus) is a New World species that feeds exclusively on blood. Its saliva contains highly potent plasminogen activators, specialized in rapid lysis of fresh blood clots. Biochemical and pharmacological evidence indicates that these plasminogen activators represent a new class of thrombolytics with pharmacological and toxicological properties superior to human tissue-type plasminogen activator, the clot dissolving agent now most frequently used in medicine. A form of the enzyme produced by recombinant DNA technology is currently employed to test this hypothesis in clinical studies.
© 2002 S. Karger AG, Basel
- Plasminogen activator
- Fibrin specificity
- Hawkey C: Plasminogen activator in the saliva of the vampire bat Desmodus rotundus. Nature 1966;211:434–435.
- Krätzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, Donner P, Schleuning W-D: The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: Cloning and expression. Gene 1991;105:229–237.
- Schleuning W-D, Alagon A, Boidol W, Bringmann P, Petri T, Krätzschmar J, Haendler B, Baldus B, Witt W, Donner P: Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): Unique fibrin specificity. Ann NY Acad Sci 1992;667:395–403.
- Petri T, Langer G, Bringmann P, Cashion L, Shallow S, Schleuning W-D: Production of vampire bat plasminogen activator DSPAα1 in CHO and insect cells. J Biotechnol 1995;39:75–83.
- Bringmann P, Gruber D, Liese A, Toschi J, Kraetzschmar J, Schleuning W-D, Donner P: Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270:25596–25603.
- Renatus M, Stubbs MT, Huber R, Bringmann P, Donner P, Schleuning W-D, Bode W: Catalytic domain structure of vampire bat plasminogen activator: A molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997;36:13483–13493.
- Kingston IB, Castro MJ, Anderson S: In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995;1:138–142.
- Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228–231.
- Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning W-D: Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79:1213–1217.
- Muschick P, Zeggert D, Donner P, Witt W: Thrombolytic properties of Desmodus (vampire bat) salivary plasminogen activator DSPα1, Alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis 1993;7:284–290.
- Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning W-D: Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Circulation 1994;90:421–426.
- Gulba DC, Praus M, Witt W: DSPA α1-properties of the plasminogen activators of the vampire bat Desmodus rotundus. Fibrinolysis 1995;9:91–96.
- Hildebrand M, Bunte T, Bringmann P, Schutt A: Development of an ELISA for the measurement of DSPAα1 (Desmodus rotundus salivary plasminogen activator) in plasma and its application to investigate pharmacokinetics in monkeys. Fibrinolysis 1995;9:107–112.
Paion GmbH, Research Center Berlin, Tegeler Weg 33
D–10589 Berlin (Germany)
Tel. +49 30 34 35 37 12, Fax +49 30 34 35 37 33
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 0, Number of References : 13
Haemostasis (International Journal on Haemostasis and Thrombosis Research)
Official Journal of the ‘Mediterranean League against Thromboembolic Diseases’
Vol. 31, No. 3-6, Year 2001 (Cover Date: May-December 2001 (Released March 2002))
Journal Editor: H.C. Hemker, Maastricht; V.V. Kakkar, London
ISSN: 0301–0147 (print), 1423–0038 (Online)
For additional information: http://www.karger.com/journals/hae
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.